Affiliation:
1. MedStar Health Research Institute; Hyattsville Maryland
Subject
Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference96 articles.
1. The cardiovascular biology of glucagon-like peptide-1;Drucker;Cell Metab,2016
2. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors;Nauck;Diabetes Obes Metab,2016
3. Aroda VR Arulandu JR Cannon AJ 2017 Insulin/GLP-1 receptor agonist combination therapy for the treatment of type 2 diabetes: are two agents better than one?
4. U.S. Food and Drug Administration Guidance for industry: diabetes mellitus -- evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes 2008 https://www.fda.gov/downloads/Drugs/.../Guidances/ucm071627.pdf
5. Evolution of exenatide as a diabetes therapeutic;Bhavsar;Curr Diabetes Rev,2013
Cited by
179 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Meta-Analysis on the Association Between DPP-4 Inhibitors and Bone Mineral Density and Osteoporosis;Journal of Clinical Densitometry;2024-01
2. Safety, pharmacokinetics and pharmacodynamics of HRS‐7535, a novel oral small molecule glucagon‐like peptide‐1 receptor agonist, in healthy participants: A phase 1, randomized, double‐blind, placebo‐controlled, single‐ and multiple‐ascending dose, and food effect trial;Diabetes, Obesity and Metabolism;2023-12-15
3. The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review;European Journal of Clinical Pharmacology;2023-11-08
4. Treatment intensification following glucagon-like peptide-1 receptor agonist treatment in type 2 diabetes: The RESTORE-G real-world study;Nutrition, Metabolism and Cardiovascular Diseases;2023-11
5. Optimizing expression, purification, structural and functional assessments of a novel dimeric incretin (GLP-1cpGLP-1);Biochimie;2023-11